This may include, but is not limite d to, redaction of the following: 

•Title: A Single-Sequence, Open-Label, 2-Period Crossover Trial to Evaluate the Effect of the 
Potent Cytochrome P-450 3A4 Inhibitor Itraconazole on the Pharmacokinetics of TAK-954 in 
Healthy Adult Subjects
Study ID: [REMOVED]
Protocol Approve Date: 03 May 2017
Certain information  within this protocol has been redacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable 
information 
or company confidential information. 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of [COMPANY_005] or partners, personal
information, or to otherwise protect the integrity of the clinical study.
TITLE PAGE
TAKEDA PHARMACEUTICALS
PROTOCOL
A Single- Sequence, Open -Label, 2- Period Crossover Trial to Evaluate the Effect of the 
Potent Cytochrome P -450 3A4 Inhibitor Itraconazole on the Pharmacokinetics of TAK -954 
in Healthy Adult Subjects
Sponsor: [COMPANY_005] Development Center Americas, Inc. 
Trial Number: TAK-954-1004
Compound: TAK-954
Date: 03 May 2017 Version/Amendment 
Number:Initial Version
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of [COMPANY_005]. Acceptance of this document constitutes the agreement by 
[CONTACT_1955][INVESTIGATOR_55718] s to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by [CONTACT_1955][INVESTIGATOR_841], his or her staff, 
and applicable institutional review committee and regulatory agencies to enable conduct of the trial.
TAK -954
Study No. TAK -954-1004 Page 2of 63
Protocol 03 May 2017
CONFIDENTIALTABLE OF CONTENTS
1.0 TRIAL SUMMARY ........................................................................................................ 7
2.0 TRIAL SCHEMATIC ..................................................................................................... 9
3.0 SCHEDU LE OF TRIAL PROCEDUR ES...................................................................... 10
4.0 INTRODUCTION ......................................................................................................... 12
4.1 Background ............................................................................................................. 12
4.2 Rationale for the Proposed Trial ............................................................................... 12
4.3 Benefit/Risk Profile .................................................................................................[ADDRESS_60747] ive................................................................................... 14
5.1.3 Exploratory  Objectives ................................................................................ 14
5.2 Endpoints ................................................................................................................. 14
5.2.1 Primary Endpo int........................................................................................ 14
5.2.2 Safety Endpo ints......................................................................................... 14
5.2.3 Exploratory  Endpo ints................................................................................. 14
6.0 TRIAL DESIGN AND DES CRIPTION ........................................................................ 16
6.1 Trial Design ............................................................................................................. 16
6.2 Rationale for Tri al Design, Dose, and Endpoints ...................................................... 16
6.2.1 Rationale of Tri al Desi gn and Dose ............................................................. 16
6.2.2 Rationale for Endpoints ............................................................................... 18
[IP_ADDRESS] PK.......................................................................................................... 18
[IP_ADDRESS] Safety Endpo ints.................................................................................... 18
[IP_ADDRESS] Exploratory  Endpo ints............................................................................ [ADDRESS_60748] ives: Timing of Procedures ......... 18
6.3 Trial Beginning and End/Complet ion....................................................................... 18
6.3.1 Definit ion of Beginning o f the Tri al............................................................ 18
6.3.2 Definit ion of End of the Trial ...................................................................... 18
6.3.3 Definit ion of Trial Discont inuat ion.............................................................. 19
6.3.4 Criteria for Premature Terminat ion or Suspension of the Trial ..................... 19
[IP_ADDRESS] Criteria for Premature Terminat ion or Suspension of Trial Sites ............. 19
[IP_ADDRESS] Procedures for Premature Terminat ion or Suspension of the Trial or the 
Parti cipation of  Trial Site(s).................................................................... 19
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS .............. [ADDRESS_60749] Replacement ................................................................................................ 24
8.0 CLINICAL TRIAL MATER IAL MANAGEMENT ...................................................... 25
8.1 Clinical Trial Drug ................................................................................................... 25
8.1.1 Clinical Trial Drug Labeling ....................................................................... 25
8.1.2 Clinical Trial Drug Inventory  and Storage ................................................... 25
8.1.3 Clinical Trial Drug Blinding ........................................................................ 25
8.1.4 Accountabilit y and Destruction of Sponsor -Supplied Drugs ........................ 25
8.1.5 Ancillary  Supplies ....................................................................................... 25
9.0 TRIAL PROCEDURES .................................................................................................26
9.1 Administrative Procedures ....................................................................................... 26
9.1.1 Inform ed Consent Procedure ....................................................................... 26
9.1.2 Assignment of Screening Numbers .............................................................. 26
9.1.3 Inclusio n and Exclusio n Cri teria.................................................................. 26
9.1.4 Medical History /Dem ographics ................................................................... 26
9.1.5 Prior and Concomi tant Medicat ion Review ................................................. 26
9.1.6 Physical Examinat ions................................................................................ 26
9.1.7 Vital Sign Measurements ............................................................................ 27
9.1.8 Height and Wei ght...................................................................................... 27
9.1.9 BMI ............................................................................................................ 27
9.1.10 12-Lead ECG .............................................................................................. 27
9.1.11 AE Monitoring ............................................................................................ 28
9.2 Labo ratory  Procedures and Assessments .................................................................. 28
[IP_ADDRESS] Clinical Laboratory  Tests ........................................................................ 28
[IP_ADDRESS] Screening ............................................................................................... 29
9.3 PK and PGx Samples ............................................................................................... 30
9.3.1 PK Evaluat ions........................................................................................... 30
9.3.2 PGx Measurements ..................................................................................... 31
TAK -954
Study No. TAK -954-1004 Page 4of 63
Protocol 03 May 2017
CONFIDENTIAL9.3.2.1 Blood Sam ple for DNA and RNA PGx Measurements ........................... 31
[IP_ADDRESS] Biological Sample Retent ion and Destruction ......................................... 31
9.4 Trial Drug Administrati on........................................................................................ 32
9.5 Confinement ............................................................................................................ 32
10.0 ADVERSE EVENTS .................................................................................................... 34
10.1 Definit ions and El ements of AEs ............................................................................. 34
10.1.1 SAEs ........................................................................................................... 36
10.2 AE Procedures ......................................................................................................... 37
10.2.1 Assigning Severit y/Intensit y of AEs ............................................................ [ADDRESS_60750] ion and Reporti ng of AEs, SAEs, and Abnormal LFTs ..................... 38
[IP_ADDRESS] Collect ion Peri od.................................................................................... 38
[IP_ADDRESS] Reporting AEs ........................................................................................ 38
[IP_ADDRESS] Reporting SAEs ...................................................................................... 39
[IP_ADDRESS] Reporting of Abnormal LFTs .................................................................[ADDRESS_60751] igators, IRBs or IECs, and Regulatory  
Authori ties.................................................................................................. 40
11.0 STATISTICAL METHODS .......................................................................................... 41
11.1 Statistical and Analyt ical Plans ................................................................................ 41
11.1.1 Analysis Sets ............................................................................................... 41
11.1.2 Analysis of Demographics and Other Baseline Characteri stics.................... 41
11.1.3 PK Analysis ................................................................................................ 41
11.1.4 Safety Analysis ........................................................................................... 42
11.1.4 .1 AEs ........................................................................................................ 42
[IP_ADDRESS] Clinical Laboratory  Evaluat ion............................................................... 42
[IP_ADDRESS] Vital Signs.............................................................................................. 42
[IP_ADDRESS] ECGs ...................................................................................................... [ADDRESS_60752] ions................................ 44
13.0 ETHICAL ASPECTS OF T HE TRIAL ......................................................................... 45
13.1 IRB and/or IEC Approval ........................................................................................ [ADDRESS_60753] igator Consent to Use of Personal Informat ion.......................................... 61
Appendix D Pregnancy and Contraception ............................................................................. 62
TAK -954
Study No. TAK -954-1004 Page 7of 63
Protocol 03 May 2017
CONFIDENTIAL1.0 TRIAL SUMMARY
Name [CONTACT_790]:
[COMPANY_005] Development Center Americas, Inc. Compound:
TAK -954
Study Number: TAK -954-1004 Phase: 1
Protocol Title: A Fixed Sequence, Open -Label, [ADDRESS_60754] of the Potent 
Cytochrome P -450 3A4 Inhibitor Itraconazole on the Pharmacokinetics of TAK -954 in Healthy Adult Subjects
Trial Design:
This is a phase 1, single -sequence, open -label, 2 -period crossover trial in approximately 10 healthy male and female 
(non–childbearing potential) subjects aged 18 and 55 years (inclusive). The trial is designed to investigate the effect of 
a potent cytochrome P -450 (CYP) 3A4 inhibitor (itrac onazole) on the pharmacokinetics (PK) of TAK -954. TAK -954 
will be administered as a single 60- minute intravenous (IV) infusion.
The trial will include a Screening Visit, Trial Period 1 (6 days), a washout (a minimum of 7 days between doses in 
Period 1 Day 1 and Period 2 Day 1), Trial Period 2 (9 days), and a Follow -up Visit. Eligible subjects will be allocated 
to the trial treatment by [CONTACT_105] -random assignment on Day 1 of Trial Period 1 and will receive a 0.2 mg single dose 
TAK -954 IV on this day and on Day 4 of Trial Period 2 at approximately the same time (between 0600 and 0900). In 
Trial Period 2, subjects will receive 200 mg once daily (QD) itraconazole orally on Days 1 to 8 at approximately the 
same time (between 0600 and 0900) and a single dose of 0.2 mg TAK -954 on Day 4. Itraconazole will be administered 
as 2 x 100 mg capsules. After completion of the trial (or after subject withdrawal), all subjects will return for a 
Follow -up Visit [ADDRESS_60755] dose of trial drug.
Primary Objective:
To evaluate the effect of the potent CYP3A4 inhibitor itraconazole on the single -dose PK of TAK -954.
Secondary Objectives:
To evaluate the safety of a single IV dose of TAK -[ADDRESS_60756] Population: Healthy  male and female (non –childbearing potential) subjects.
Number of Subjects:
Approximately 10 subjects will complete this trial.Number of Sites:
1 site
Dose Levels:
TAK -954 0.2 mg
Itraconazole 200 mg QDRoute of Administration:
TAK -954 IV 
Itraconazole oral
Duration of Treatment:
Two doses of TAK -954.
Eight doses of itraconazole.Period of Evaluation:
Approximately 7 to 8 weeks
Main Criteria for Inclusion:
Healthy  male and female (non –childbearing potential) subjects who are aged 18 to 55 years, inclusive, with a body 
mass index (BMI) between 18 to 30 kg/m2, and a body weight >50 kg.
Main Criteria for Exclusion:
Subjects who have a history of clinically significant endocrine, gastrointestinal (GI [including motility disorder and 
intestinal obstruction]), cardiovascular, hematological, hepatic, immunological, renal, respi[INVESTIGATOR_696], genitourinary ,or 
major neurological (including stroke and chronic seizures) abnormalities or diseases will be excluded from the trial.
TAK -954
Study No. TAK -954-1004 Page 8of 63
Protocol 03 May 2017
CONFIDENTIALEndpoints and Criteria for E valuation:
Primary endpoints:
Plasma PK parameters (maximum observed concentration [C max] and area under the concentration -time curve from 
time [ADDRESS_60757] quantifiable concentration [AUC ∞]) for TAK -954 wi ll 
be analyzed on Day 1 of Trial Period 1 and on Day 4 of Trial Period 2.
Safety endpoints: 
Safety and tolerability will be assessed through physical examinations, electrocardiograms (ECGs), vital signs, and 
laborato ry assessments as well as collection of spontaneous adverse events.
Statistical Considerations:
Pharmacokinetics :
The PK parameters of TAK -954 (and metabolites, if possible) will be summarized by [CONTACT_55726]. Linear and semilogarithmic plots of the mean and individual concentration -time curves will be provided. 
Individual plasma concentration and PK parameter data will be presented in the data listing. 
For evaluation of potential effect of itraconazole on TAK -954 PK, paired t -tests and associated confidence intervals 
will be determined on the natural logarithms of C maxand AUCs to assess the exposure between regimens (TAK -954 
alone and TAK -954 with itraconazole). The geometric mean of the relative bioavailability of the TAK -954 with 
itraconazole regimen relative to the TAK -954 alone regimen and the associated 90% confidence intervals will be 
determined by [CONTACT_55727] -transformed 
parameters.
Safety:
Safety data will be presented by [INVESTIGATOR_24858]. Treat ment -emergent adverse events (TEAEs) will be summarized by [CONTACT_55728]. Clinical laborator y variables, ECGS, and vital signs parameters 
(uncorrected and corrected QT intervals, PR, and QRS and heart rate) will be summarized with descriptive statistics 
for period baseline, postdose, and change from period baseline to postdose values.
Sample Size Justification: 
Approximately 10 subjects will complete this trial. With this sample size, a 2-sided 95.0% CIfor the geometric mean 
ratio of C maxfor TAK -[ADDRESS_60758] 90% probability of excluding 
1.25 (the upper bound of the bioequivalence range) if itraconazole increases the C maxfor TAK -[ADDRESS_60759] 50%. 
This calculation assumes that the CIis based on the t statistic, that the distance from the mean to the lower bound of the 
CIon the natural -log scale is 0.182, and that the true SDof differences on the natural -log scale is 0.[ADDRESS_60760] variation 
observed for area under the concentration -time from 0 to t in that cohort (SD=0.129), a 2-sided 95.0% CIfor the 
geometric mean ratio of AUC ∞for TAK -[ADDRESS_60761] greater than 
99% probability of excluding 1.25 if itraconazole increases AUC ∞ for TAK -[ADDRESS_60762] 50%. 
Subjects who drop out may be replaced at the discretion of the investigator in consultation with th e sponsor. 
TAK -954
Study No. TAK -954-1004 Page 9of 63
Protocol 03 May 2017
CONFIDENTIAL2.0 TRIAL SCHEMATIC
PK=pharmacokinetic.

TAK-954
Study No. TAK-954-1004 Page 10 of 63
Protocol 03 May 2017
CONFIDENTIAL3.0 SCHEDULE OF TRIAL PROCEDURES
Assessment Screening Trial Period 1 (a) Trial Period 2Follow-up/Early 
Termination
Day -[ADDRESS_60763] 
dose of trial drug
Administrative Procedures
Informed consent X
Inclusion/exclusion criteria X X
Medical history/demographics X
Prior and concomitant medication review--------------------------------------------Conti nuous re view-------------------------------------------------
Clinic Procedures/Assessments
Full physical examination X X X
Semirecumbent vital signs (heart 
rate [HR], systolic blood pressure [SBP] and diastolic 
blood pressure [DBP]X X ( b ) XX X X XX
(b)XX X X
Vital signs (respi[INVESTIGATOR_697], oral 
[at the floor of the mouth]/tympanic temperature) 
rateX X (b) X
Height X
Weight X
Body mass index (BMI) X
Standard 12-lead 
electrocardiogram (ECG)X X (b) X X X
(b)XX
Adverse event (AE) mon itoring ---------------------------------------------Contin uous re view------------------------------------ -------------
Laboratory Procedures/Assessments
Serum chemistry X X X X X X
Hematology X X X X X X
Urinalysis X X X X X X
Serum follicle-stimulating XCCI
TAK-954
Study No. TAK-954-1004 Page 11 of 63
Protocol 03 May 2017
CONFIDENTIALAssessment Screening Trial Period 1 (a) Trial Period 2Follow-up/Early 
Termination
Day -[ADDRESS_60764] 
dose of trial drug
hormone (FSH)
Urine drug screen X X X
Urine alcohol test/alcohol breath test (d)XX X
HIV test X
Hepatitis panel X
Pharmacokinetics (PK) Evaluations
Plasma samples for TA K-954 (e) X X X X X X X X X X
Urine sample for TAK-954 PK 
(f)XX X X X X
Pharmacogenomic (PGx) Evaluations
Blood sample for DNA PGx X
Blood sample for RNA PGx X
Drug Administration
TAK-954 dosing X X
Itraconazole dosing XX X X X X X
Other
Confinement X X X X X X X X X X
Meals X X X X X X X X X X X
(a) A minimum of 7 days between doses in Period 1 Day 1 and Period 2 Day 1. 
(b) Assessments at predose (within 30 minutes), 1, 2, 4, 8, and 12 hours postdose (relative to TAK-954 start of infusion).(c)(d) An alcohol breath test may be performed at the discretion of the investigator.(e) Time points for PK blood samples for TAK-954: predose (within 30 minutes), and 0.33, 0.5, 0.67, 1 (just after the end of in fusion), 1.5, 2, 3, 4, 6, 12, 24, 36, 48, 72, 96, and 
120 hours postdose (relative to TAK-954 start of infusion).
(f) Urine collected at predose, [ADDRESS_60765] inal (GI) 
motility, develop enteral feeding into lerance, which can lead to several co mplications including 
not m eeting daily  calorie and protein requirements [1]. The addition of malnutrit ion in these 
patients i s associ ated wi th impairment of immuno logical funct ion, increased risk o f infect ion, 
prolongati on of  mechanical  ventilation,increased length of intensive care unit and hospi[INVESTIGATOR_4408],
and ult imately higher mortalit y [2,3] . 
TAK -[ADDRESS_60766] ive and potent serotonin type 4 
(5-HT4)receptor agonist that exhibits prokinet ic activit y throughout the GI tract [4]. 
TAK -[ADDRESS_60767] igated in healthy subjects at single oral doses from 0.1 to 20 mg, mult iple 
oral doses fro m 0.2 to 10 mg daily for 10 days, and m ultiple intravenous (IV) doses from 0.1 to 
0.5mg daily for 5 days. TAK -954 has been shown to undergo oxidat ive metabo lism in vitro in 
human liver microso mes, although it was relat ively stable when incubated with cry opreserved 
human hepatocy tes (half -life [t 1/2])>17hours).
The purpose of this trial is to investigate the effect of a potent CYP3A4 inhibitor on the PK of IV 
TAK -954 in healt hy males and females. Itraconazole has been chosen as it is recommended by [CONTACT_5212] (FDA) and European Medicines Agency (EMA) as a suitable 
potent c ytochrome P -450 (CYP) 3A4 inhibitor for use in drug- drug interaction (DDI) studies. An 
IV dose of 0.2 mg TAK -954 daily  has been selected as a dose that is predicted to be within the 
clinically relevant range, but is lower than the maximum mult iple IV dose (0.5mg) that has been 
investigated so far, to allow for any  increases in exposure that may be observed with metabo lic 
inhibit ion.
Please refer to the TAK -[ADDRESS_60768] igator’s Brochure for complete informat ion on the 
investigat ional product and the most rece nt itraconazole product insert for the appropriate region.
This tri al will be conducted in com pliance wi th the protocol , Good Clinical Pract ice (GCP), and 
the applicable regulatory  requi rement(s).
4.2 Rationale for the Proposed Trial
This is a phase 1, single -sequence, open -label, 2-period crossover tri al in 10 heal thy male and 
female (non –childbearing potential) subjects. The trial is designed to invest igate the effect of a 
potent CYP3A4 inhibitor (itraconazo le) on the PK of TAK -954. TAK -954 will be administer ed as 
a single 60- minute IV infusio n.
4.3 Benefit/Risk Profile
As thi s is a tri al in heal thy subjects, there is no expected clinical benefit to the trial participants. 
Potenti al risks are based on clinical findings, the mechanism of act ion, and nonclinical fin dings. 
TAK -954
Study No. TAK -954-1004 Page 13of 63
Protocol 03 May 2017
CONFIDENTIALThere is minimal risk associated with trial procedures including phlebotomy (limited to <500 mL) 
and noninvasive procedures including vital sign assessments and ECGs. The principal mit igation 
for these ri sks includes appropriate select ion of the tr ial populations, the CRU setting, which 
permits close mo nitoring and rapid institution of appropriate care as needed, and the specified 
monitoring procedures. Overall, the risk:benefit is considered appropriate for this trial.
TAK-[ADDRESS_60769] of the potent CYP3A4 inhibitor 
itraconazole on the single-dose PK of TAK-954.
5.1.2 Secondary Objective
The secondary objectives of the trial are to evaluate the safety of single-dose IV doses of TAK- 954 
in the presence and absence of a potent CYP3A4 inhibitor.
5.1.3 Exploratory Objectives
Exploratory objectives of this trial include: 
5.2 Endpoints
5.2.1 Primary Endpoint
The primary endpoint of the trial is the following PK parameters on Day 1 of Trial Period 1 and 
Day 4 of Trial Period 2:
!Maximum observed concentration (C max).
!Area under the concentration-time curve from time [ADDRESS_60770] quantifiable concentration (AUC ∞).
5.2.2 Safety Endpoints
Safety endpoints include the following: 
Safety and tolerability will be assessed through physical examinations, ECGs, vital signs, and 
laboratory assessments, and collection of spontaneous AEs.
5.2.3 Exploratory Endpoints
Exploratory endpoints will be assessed through the following parameters: 
PK parameters:CCI
CCI
TAK-954
Study No. TAK-954- 1004 Page 15 of 63
Protocol 03 May 2017
CONFIDENTIALPharmacodynamic parameters:CCI
CCI
TAK-954
Study No. TAK-954- 1004 Page 16 of 63
Protocol 03 May 2017
CONFIDENTIAL6.0 TRIAL DESIGN AND DESCRIPTION
6.1 Trial Design 
This is a phase 1, single-sequence, open-label, 2-period crossover trial in approximately 
10 healthy male and female (non–childbearing potential) subjects. The trial is designed to 
investigate the effect of a potent CYP3A4 inhibitor (itraconazole) on the PK of TAK-954. 
TAK-954 0.2 mg will be administered as  a single 60-minute IV infusion. 
The trial will include a Screening Visit, Trial Period 1 (6 days), a washout (a minimum of 7 days 
between doses in Period 1 Day 1 and Period 2 Day 1), Trial Period 2 (9 days), and a Follow-up 
Visit. Blood samples for assessment of TAK-[ADDRESS_60771] dose of trial drug in each trial peri od. 
Samples may be assayed for TAK-954 metabolites . TAK-954 and its metabolites will also be 
assayed in urine, data permitting and if deemed possible.
Whole blood samples for DNA PGx analysis and RNA isolation will be collected predose on 
Day 1of Trial Period 1. 
Safety will be assessed by [CONTACT_55729], ECGs, vital signs, safety laboratory tests, and 
physical examinations throughout each dosing period. 
After completion of the trial (or after subject withdrawal), all subjects will return for a Follow-up 
Visit, approximately [ADDRESS_60772]. TAK-954 has been investigated in healthy subjects 
at single oral doses from 0.1 to 20 mg, multiple oral doses from 0.2 to 10 mg once daily (QD) for 
10 days, and multiple IV doses from 0.1 to 0.5 mg QD for 5 days. A single IV dose of 0.5 mg 
TAK-954 has also been investigated in critically ill patients with enteral feeding intolerance and 
compared with metoclopramide. After multiple IV infusion dosing in healthy subjects (0.1 and 
0.5 mg with a 1-hour infusion), TAK-954 concentrations declined in a biphasic manner, with mean 
t1/2 values ranging from 18.0 to 18.9 hours on Day 5. TAK-954 steady state was achieved by [CONTACT_2006] 3 
with minimal accumulation of TAK-954 after multiple IV dosing of 0.5 mg. The increase in 
exposure from the 0.1 mg to 0.5 mg IV dose was approximately dose proportional, and the mean 
amount of TAK-954 excreted unchanged in urine on Day 5 ranged from 27.7% to 31.6%. In 
subjects who were critically ill and received 0.5 mg by [CONTACT_16228], the PK exposure was slightly 
lower relative to that observed in healthy subjects.
Two active metabolites were identified nonclin ically, but TAK-954 was not extensively 
metabolized to either of these metabolites after oral dosing (mean C maxand area under the 
concentration-time curve from time 0 to 48 hours metabolite to parent ratios ranged from 0.0008 to CCI
TAK -954
Study No. TAK -954-1004 Page 17of 63
Protocol 03 May 2017
CONFIDENTIAL0.004). Renal excretion of these metabo lites was also l ow wi th concentrati ons in urine generally 
below the limit of detection. Evidence of GI prokinet ic act ivity in healthy subjects (increased 
bowel  movement frequency, l ooser stool  consistency , and decreased time to first bowel 
movement) was observed at all dose levels after receiving single and mult iple doses (oral and IV). 
In [ADDRESS_60773] comm only reported treatm ent-related AEs in TAK -954 subjects overall were headache 
and diarrhea. No dose -related trends were evident in the AE data across the 0.2, 1, or 5 mg dose
groups, but 2 of 3 subjects receiving 10 mg were discontinued because of an AE (mild intermittent 
atrioventri cular dissociation, which reso lved without intervent ion). There were no safet y signals in 
the clinical laboratory  or respi [INVESTIGATOR_55719] m ultiple dose administration. Mean blood 
pressure (BP) and heart rate (HR) remained in the normal range for all groups throughout the trial. 
However, there was a trend toward lower BP and elevated HR in the standing posit ion for 
TAK -954 subjects, but no dos e response was apparent. In addit ion, there was one AE related to BP 
(orthostati c hypotensio n in a subject who received 5 mg TAK -954).
After IV doses in healthy subjects, TAK -954 was generally  well  tolerated at doses ranging fro m 
0.1 to 0.5 mg QD for 5 con secut ive days. No serious adverse events (SAEs) were reported. The 
most comm on AEs (i e, headache and postural dizziness) were not clinically significant and 
resolved spontaneously. Amo ng the AEs reported, [ADDRESS_60774] dose (ie, postural tachycardia and postural 
dizziness) that resolved spontaneously , and were not observed upon challenge. After single 
infusio ns of TAK -954 0.5 m g in subjects who were crit ically ill wit h enteral fe eding intol erance, 
no subjects had an AE that led to trial discont inuat ion or interruption of treatment. Vital sign 
changes fro m Baseline noted during treatment were minimal and ty pi[INVESTIGATOR_55720]. 
No clinically  relevant changes in ECGs in either treatm ent group were observed.
TAK -954 has been shown to undergo oxidative metabolism in vitro in human liver microsomes, 
though it was relat ively stable when incubated with cry opreserved human hepatocy tes (t 1/2
>17hours).
The purpose of this trial is to investigate the effect of a potent CYP3A4 inhibitor on the PK of IV 
TAK -954 in healthy subjects. Itraconazo le has been chosen as it is recommended by [CONTACT_55730] a suitable potent CYP3A4 inhibitor for use in DDI studies. An IV dose of 0.2 mg 
TAK -954 has been selected as a dose that is predicted to be wit hin the clinically relevant range, but 
is lower than the maximum mult iple IV dose (0.5mg) that has been invest igated so far, to allow for 
any increases in exposure that may be observed with me tabolic inhibi tion. 
TAK-954
Study No. TAK-954- 1004 Page 18 of 63
Protocol 03 May 2017
CONFIDENTIAL6.2.2 Rationale for Endpoints
[IP_ADDRESS] PK 
The primary endpoint for this trial consists of standard PK variables (C maxand AUC ∞) to 
determine the effect of itraconazole on the PK of TAK-954 in healthy subjects.
[IP_ADDRESS] Safety Endpoints
Key safety endpoints will be assessed through monitoring of AEs, vital signs, ECGs, clinical 
laboratory results, and physical examinations.
[IP_ADDRESS] Exploratory Endpoints
6.2.3 Critical Procedures Bas ed on Trial Objectives: Timing of Procedures
For this trial, the collections of the blood samples for TAK-954 (PK) are the critical procedures. 
!At any postdose time point, the blood samples for TAK-954 (PK) needs to be collected as close 
to the exact nominal time point as possible.
!All other procedures should be completed as close as possible, either before or after the 
prescribed/scheduled time.
– ECG and vital signs measurements should be performed before the nominal time of the 
TAK-954 (PK) if scheduled together.
!The order of priority can be changed during the trial with joint agreement of the investigator 
and the sponsor.
!Any nonscheduled procedures required for urgent evaluation of safety concerns take 
precedence over all routine scheduled procedures.
6.3 Trial Beginning and End/Completion
6.3.[ADDRESS_60775] planned or follow-up 
visit/interaction associated with a p lanned visit (this can be a phone contact), discontinues from the 
trial or is lost to follow-up (ie, the investigator is unable to contact [CONTACT_423]).CCI
TAK -954
Study No. TAK -954-1004 Page 19of 63
Protocol 03 May 2017
CONFIDENTIAL6.3.3 Definition of Trial Discontinuation
Trial discont inuat ion because of nonsafet y reasons, such as:
A finding (eg, PK, PD, efficacy, bio logic targets) from another nonclinical or clinic al trial 
using the trial treatment(s) results in the trial being stopped for a non –safet y-related reason. 
Data from co mparator(s), drug(s) of the same class, or methodology(ies) used in this trial 
beco me available and results in the trial being stopped fo r a non –safet y-related reason. 
The tri al is stopped because of nonscientific and nonsafet y reasons, such as slow enrollment.
Trial discont inuat ion because of safet yreasons: 
Early trial terminat ion because of unant icipated concerns o f safety  to the trial subjects arising 
from clinical or preclinical trials wit h the trial treatment(s), comparator(s), drug(s) of the same 
class, or m ethodol ogy(ies) used in this trial.
6.3.4 Criteria for Premature Termination or Suspension of the Trial
[IP_ADDRESS] Criteria for Premature Termin ation or Suspension of Trial Sites
A trial site may  be terminated prem aturely  or suspended if the site (including the invest igator) is 
found in significant vio lation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the trial , or as otherwise permitted by  [CONTACT_55731].
[IP_ADDRESS] Procedures for Premature Termination or Suspension of the Trial or the Participation of 
Trial Site(s)
In the event that the sponsor, an inst itutional review board (IRB), or regulatory  autho rity elects to 
terminate or suspend the trial or the participat ion of an invest igational site, a trial -specific 
procedure for early terminat ion or suspensio n will be provided by  [CONTACT_456]; the procedure will 
be fo llowed by [CONTACT_55732] s during the course of terminat ion or trial suspension.
TAK -954
Study No. TAK -954-1004 Page 20of 63
Protocol 03 May 2017
CONFIDENTIAL7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
7.[ADDRESS_60776]:
1. Understand the trial procedures and agree to partici pate by  [CONTACT_55733].
2.Be willing and able to comply with all trial procedures and restrict ions.
3.Be a man or wom an(with no child bearing potential) aged [ADDRESS_60777] a BMI ≥18 and ≤30 kg/m2and a body  weight >50 kg at the Screening Visit.
5.Be a nonsmoker who has not used tobacco -or nicotine -containing products (eg, nicotine 
patch) for at least 6 months before administration of the init ial dose of tri al drug/invasive 
procedure.
6.Be judged to be in good health by [CONTACT_093], based on clinical evaluat ions including 
laboratory  safety tests, m edical history , physical  examinat ion, 12 -lead ECG, and vital sign 
measurements performed at the Screening Visit and before administration of the init ial dose of 
trial drug.
7.Meet the fo llowing bi rth control  requi rements:
–Is a m ale subject who i s sterile or agrees to use an appropriate method of contraception, 
including a condom with or without spermicidal cream or jelly, fro m trial drug 
administration on th e first day  of the first dose until [ADDRESS_60778] –bilateral vasectomy procedure 
befor e trial drug administrati on on the first day  of the first dose. A male subject whose 
vasectomy  procedure was perform ed less than [ADDRESS_60779] ions as a nonvasectomiz ed m an. 
Appropriate documentation of surgical procedure should be provided.
–Is a male subject who agrees to not donate sperm from trial drug administration on the first  
day of the first dose until [ADDRESS_60780] dose of 
trial drug.
–Is a female subject with no childbearing potential, defined by [CONTACT_2669] 1 of the fo llowing 
criteria:
a)Postmenopausal  (defined as 12 m onths of spontaneous amenorrhea in females aged 
>45 y ears, 6 months of spontaneous amenorrhea in females aged >45 years with seru m 
FSH l evels >40 m IU/mL). Appropri ate docum entati on of  FSH levels is required.
b)Surgically sterile by  [CONTACT_55734]/or bilateral  oophorectomy  with appropri ate 
docum entati on of  surgical  procedure.
TAK -954
Study No. TAK -954-1004 Page 21of 63
Protocol 03 May 2017
CONFIDENTIALc)Had a tubal ligat ion with appropr iate docum entati on of  surgical  procedure.
d)Has a congenital condit ion result ing in no uterus.
7.[ADDRESS_60781]: 
1.Has a history  of clinically significant endocrine, gastrointestina l (including motilit y disorder 
and intest inal obstruction), cardiovascular, hematological, hepat ic, immuno logical, renal, 
respi [INVESTIGATOR_696] , geni tourinary , or m ajor neurol ogical (including stroke and chronic seizures) 
abnorm alities or di seases.
2.Has parti cipated in another invest igational tri al within 4 weeks before the pretrial (Screening) 
visit. The [ADDRESS_60782] trial  procedure and/or AE 
related to the tri al procedure in the previous trial to the pretrial/Screening Visi t of the current 
trial. 
3.Is an emplo yee or immediate family member (eg, spouse, parent, child, sibling) of the sponsor.
4.Has a history  of cancer (m alignancy).
5.Has a history  of significant m ultiple and/or severe allergies (eg, food, drug, latex allergy ) or 
has had an anaphylact ic reaction or significant intolerabilit y to prescript ion or nonprescript ion 
drugs or food.
6.Has a posit ive alcoho l or drug screen.
7.Is a l actati ng/nursing wo man.
8.Had major surgery , donated or l ost 1 unit of blood (approximately 500 mL) within [ADDRESS_60783] dose of trial drug.
9.Has a known hypersensit ivity to any  com ponent of the formulat ion of TAK -954 or related 
compounds, or to i traconazol e (see Product Insert).
10.Is unable to refrain fro m or anti cipates the use of any  medicat ion, including prescript ion and 
nonprescript ion drugs or herbal remedies, beginning approximately 7 days before 
administration of the init ial dose of trial drug, throughout the trial (including washout intervals 
between tri al periods), until  the Foll ow-up Visi t.There may be certain medications that are 
permitted, see Section 7.3.
11.Has a history  of alcohol  consum ption exceeding [ADDRESS_60784] drinks per day on average (1 glass
is approximately equivalent to: beer [354 mL/12 ounces], wine [118 mL/4 ounces], or dist illed 
spi[INVESTIGATOR_2120] [29.5 mL/1 ounce] per day ).
12.Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately 
equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated 
beverages per day .
13. Has a substance abuse disorder.
TAK -954
Study No. TAK -954-1004 Page 22of 63
Protocol 03 May 2017
CONFIDENTIAL7.3 Excluded Medications ,Supplements, and Dietary Products
Use of excluded agents (prescription or nonprescription) or dietary products is outline in Table 7.a.
Table 7.a Excluded Medications, Supplements, and Dietary Products
CategoryBetween Screening and Enroll ment 
(Days -28 to Predose [Day 1])Randomization Post-Enrollment 
(Day 1) to Follow -upVisit
Tobacco -and 
nicotine -containing 
productsCompletely restricted Completely restricted
Cannabis products Completely restricted Completely restricted 
Alcohol Completely restricted 7 days before 
dosingCompletely restricted 7 days before 
dosing 
At all other times no more than 
3units/day
Xanthine and/or caffeine Completely restricted 24 hours before 
dosingCompletely restricted 24 hours before 
dosing 
At all other times no more than 
6units/day
Medications Completely restricted 7 days before 
dosingCompletely restricted (a)
Food substance
Grapefruit /grapefruit juice Completely restricted [ADDRESS_60785] green (b) Completely restricted 7 days before 
dosingCompletely restricted
Charbroiled meat Completely restricted 7 day s before 
dosingCompletely restricted
(a) If medications are required to treat an AE, certain medications may be allowed after discussion and agreement 
between the sponsor and principal investigator.
(b) Mustard green family includes kale, broccoli, watercress, collard greens, kohlrabi, Brussel sprouts, and mustard. 
7.[ADDRESS_60786] abstain fro m all food and drink (except water) at least [ADDRESS_60787] (moderate -fat) breakfast 1.[ADDRESS_60788] ively, on all days. An evening snack will also be permitted. The caloric content and 
composition of  meals will be the same in each trial period. After the 24 -hour postdose (Day  1 of 
Trial Period 1 and Day 4 of Trial  Period 2) procedures have been completed, subsequent meals and 
snacks will be unrestricted in caloric content, composit ion, and t iming.
7.4.[ADDRESS_60789] ivity (eg, wei ght lift ing, running, 
bicyc ling) from the Screening Visit until the Fo llow-up Visit.
7.[ADDRESS_60790]’s healt h or the subject is unwilling to continue 
because of the AE.
2.Liver Funct ion Test (LFT) Abnormalit ies
In multidose studi es, tri al drug shoul d be discont inued immediately wit h appropriate clinical 
follow-up (including repeat laboratory tests, until a su bject’s laboratory  profile has returned to 
norm al/baseline status, see Section [IP_ADDRESS] ), if the fo llowing ci rcumstances occur at any  time 
during t rial drug treatm ent:
–
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >8 times the upper 
limit of normal (ULN), or
–ALT or AST >5×ULN and persists for more than 2 weeks, or
–ALT or AST >3×ULN in conjunct ion with elevated total bilirubin >2× ULN or 
internat ional norm alized rati o >1.5, or
–ALT or AST >3×ULN with appearance of fat igue, nausea, vomit ing, ri ght upper quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%).
3.Significant protocol  deviat ion. The discovery  that the subject f ailed to meet protocol entry  
criteria or di d not adhere to protocol requirements, and cont inued participat ion poses an 
unacceptable risk to the subject’s healt h.
4.Lost to follow -up. The subject did not return to the clinic, and attempts to contact [CONTACT_55735]. Attempts to contact [CONTACT_39784]’s source 
docum entation.
5.Voluntary  withdrawal. The subject (or subject’s legally  acceptable representative) wishes to 
withdraw from  the tri al. The reason for withdrawal, if provided, should be recorded in the 
electroni c case report form (eCRF). 
TAK -954
Study No. TAK -954-1004 Page 24of 63
Protocol 03 May 2017
CONFIDENTIALNote: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  underlying reason should be recorded (ie, withdrawal becau se of 
an AE should not be recorded in the “vo luntary withdrawal” category ).
6.Trial terminat ion. The sponsor, IRB, or regulatory  agency  terminates the tri al.
7.[ADDRESS_60791] ’s trial parti cipat ion at any  time during the trial when 
the subject m eets the tri al terminat ion criteria described in Sect ion 7.5. In addit ion, a subject may 
discontinue his or her participat ion without giving a reason at any  time during the trial. Should a 
subject’s participat ion be di scontinued, the primary  criterion for terminat ion must be recorded by  
[CONTACT_3170]. In addit ion, efforts should be made to perfo rm all procedures scheduled for the 
Early Terminat ion Visit. 
7.[ADDRESS_60792]’s treatment assignment and allocat ion number. 
TAK -954
Study No. TAK -954-1004 Page 25of 63
Protocol 03 May 2017
CONFIDENTIAL8.0 CLINICAL TRIAL MATER IAL MANAGEMENT
8.1 Clinical Trial Drug 
Details regarding the composit ion and extemporaneous preparation of the active ingredient are 
found in the Pharmacy  Manual, Compounding Instructions, and/or similar documents. Clinical 
trial drug will  be packaged to support enrollment and replacement subjects as required. When a 
replacement subject i s requi red, the sponsor needs to be contact[CONTACT_55736].
Itraconazo le will be supplied by [CONTACT_21655].
8.1.[ADDRESS_60793] be stored in a secure, limit ed-access locat ion under the storage condit ions 
specified on the label. Inventory  (recei pt and di spensing) of trial drug must be recorded by  [CONTACT_55737]. 
8.1.3 Clinical Trial Drug Blinding
This is an open -label trial; therefore, the sponsor, investigator, and subject will know the treatment  
administered.
8.1.[ADDRESS_60794] ions describe the trial procedures and data to be collected as indicated in the 
Schedule of Trial Procedures (Section 3.0). For each procedure, subjects are to be assessed by [CONTACT_55738]. Please note that it may beco me necessary to 
perform  the f ollowing procedures at unsched uled time peri ods, per the discret ion of the 
investigator. For informat ion regarding procedures that are scheduled concurrent ly, see 
Secti on6.3.[ADDRESS_60795] screening assessments performed prior to the trial, the data from 
the general/site screening could be included/used in the trial for those who were enrolled, as long 
as the procedure was performed within the protocol screening/enro llment window. A generic site 
screening form may  be used.
9.1.[ADDRESS_60796] ion 7.0.
9.1.4 Med ical History/Demographics
Qualified site personnel are to collect subject significant medical history  (past and ongoing) per 
the site’s standard of care and appropriate clinical judgment as well as subject demographics. 
9.1.[ADDRESS_60797] physical examinat ions.
TAK -954
Study No. TAK -954-1004 Page 27of 63
Protocol 03 May 2017
CONFIDENTIAL9.1.7 Vital Sign Measurements
Body  temperature will be measured with an oral (temperature taken at floor of the mouth) or 
tympanic thermo meter. The same method (eg, oral or tympanic) must be used for all subsequent 
measurements for each individual subject and should be the same for all subjects.
Subjects should rest in a semirecumbent position for at least 5 minutes before having vital sign 
measurements obtained. Vital signs will include HR, sy stolic bl ood pressure, and di astolic bl ood 
pressure. The same method (eg, same and appropriately sized cuff, manual, or automated) must be 
used for all measurements for each individual subject and should be the same for all subjects. 
Subjects will cont inue to rest in a semirecumbent posit ion from the time of dosing unt il 4 hours 
postdose except to stand for the measurement of standing vital signs (if needed) or other 
trial-related procedure. 
9.1.[ADDRESS_60798]’s shoes off and jacket or co at removed.
9.1.9 BMI
BMI equals a person’s weight in kilograms divided by  [CONTACT_55739] (BMI=kg/m2). 
Body  weight and height will be obtained with the subject’s shoes off and jacket or coat removed. 
BMI will be rounded to the nearest whole number according to the standard convent ion of 
0.1to0.[ADDRESS_60799] 5 minutes before each ECG 
measurement.
QT intervals wit hFridericia correcti on m ethod (QTcF) will be used to calculate QT intervals in 
this trial.
Before each trial period, a predose ECG will be obtained within approximately [ADDRESS_60800] demonstrates an increase in QTcF interval ≥40 msec co mpared with a predose baseline 
measurement, the ECG will be repeated w ithin 5 minutes. The average value o f the QTcF interval 
from the 2 ECGs will represent the value at that time point. If the average QTcF interval increase 
from Baseline for any  postdose time point is ≥[ADDRESS_60801] 4 hours or until the QTcF is within 40 msec of 
the baseline value. If prolongation o f the QTcF interval ≥[ADDRESS_60802] may  be appropri ate and the sponsor should b e notified.
TAK -954
Study No. TAK -954-1004 Page 28of 63
Protocol 03 May 2017
CONFIDENTIALIf the QTcF interval is ≥[ADDRESS_60803] shoul d be tel emetry -monitored (until  the QTcF i s 
<500 msec) or should be considered for transfer to a location wher e clo ser monitoring is available.
If the subject has unstable hemodynamics, or has any clinically significant dysrhyt hmias noted on 
telemetry , the subject should be immediately  transferred to an acute care setting for definit ive 
therapy . 
If repeat ECGs ar e required, the clinical site will decide whether to leave the electrodes in place or 
mark the posit ion of the electrodes for subsequent ECGs. To mark the position o f the electrodes, 
12-lead electrode sites will be marked on the skin of each subject with a n ECG skin marker pen to 
ensure reproducible electrode placement.
The fo llowing ECG param eters will be recorded: HR, PR -interval, QRS -durati on, QT -interval, 
QTcF -interval, and the interpretation of the ECG profile by [CONTACT_458].
9.1.[ADDRESS_60804]’s medical 
history . A com plete descri ption of  AE collect ions and procedures i s provi ded in Sect ion10.0.
9.[ADDRESS_60805] on the days stipulated in the Schedule 
of Trial Procedures (Section 3.0).
[IP_ADDRESS] Clinical Laboratory Tests
Chemistry 
Chemistry  evaluat ions will consist of the fo llowing standard chemistry  panel:
Albumin Alkaline phosphatase
ALT AST
Blood urea nitrogen Calcium
Bicarbonate Chloride
Creatinine Glucose
Gamma -glutamyl transferase Sodium
Potassium Bilirubin (total), if above ULN, will be fractionated
Protein (total)
TAK -[ADDRESS_60806] of the following tests:
Erythrocy tes (red blood cells [RBCs]) Hemoglobin
Hematocrit Platelets
Leukocytes (white blood cells [WBCs]) with absolute 
differential
Urinalysis
Urinalysis will consist of the fo llowing tests:
Protein Glucose
Blood Nitrite
Urine microscopy  will be perform ed if urinalysis is abnormal. Microscopy  consists of 
RBC/high -power field, WBC/high -power field, and casts.
Urine Drug Screen
A urine drug screen will include the fo llowing tests: 
Amphetamines 3,4-methy lenedioxy -methamphetamine (MDMA)
Barbiturates Methadone/metabolite
Benzodiazepi[INVESTIGATOR_55721]/metabolite Oxycodone/oxy morphone
Cannabinoids Phency clidine
Cocaine/metabolites
Alcohol Screen
Subjects will undergo a urine alcoho l test. An alcoho l breath test m ay be perform ed at the 
discreti on of  the invest igator.
[IP_ADDRESS] Screening
Serum
Serum  evaluat ions will include the fo llowing tests:
HIV test FSH (females only)
Hepatitis panel, including HBsAg and anti -HCV
TAK -954
Study No. TAK -954-1004 Page 30of 63
Protocol 03 May 2017
CONFIDENTIAL9.3 PK and PGx Samples
A porti on of  the DNA sample will be analyzed for the presence of allelic variants in drug 
metabo lizing enzymes, drug transporters, or putative drug targets that may contribute to the 
variability in the PK of TAK -954 (Drug Metabolism Enzymes and Transporters. 
As PGx is an evo lving science, many genes and their funct ions are not yet fully understood. Future 
data m ay suggest a rol e of these genes in drug response, which may lead to addit ional 
hypothesis -generating exploratory  research and diagnostic development on stored samples.
Samples for PK analysis will be collected as specified in the Schedule of Trial Procedures 
(Secti on3.0). Please refer to the Laboratory Manual for informat ion on the collect ion, processing, 
and shipment of samples to the central laboratory . 
It is ant icipated that the total blood volume drawn for the tri al will be approximately [ADDRESS_60807] asma PK parameters for TAK -954 will be calculated on Day  1 of Trial Period 1 
and Day 4 o f Trial Peri od 2: 
Cmax.
AUC ∞.
t1/2.
Other PK parameters may be calculated if deemed necessary for the interpretation of the data. All 
efforts will be made to obtain the PK samples at the exact no minal t ime relat ive to dosing. 
However, samples obtained wit hin 10% o f the no minal t ime fro m dosi ng will not be captured as a 
TAK-[ADDRESS_60808] date and time of the dosing and sample collection is noted 
on eCRF.
9.3.2 PGx Measurements
[IP_ADDRESS] Blood Sample for DNA and RNA PGx Measurements
When sampling of whole blood for PGx analysis o ccurs, every subject must sign an informed 
consent/be consented in order to participate in the trial. PGx is a component of the trial; 
participation is mandatory.
PGx is the study of variations of DNA and RNA ch aracteristics as related to drug response. There 
is increasing evidence that an individual’s genetic background may impact the PK (absorption, 
distribution, metabolism, and excretion), pharmacodynamics (pharmacologic effects), and/or the 
clinical outcome (efficacy and/or safety).
PGx research in this trial may be conducted to understand how individual genetic variation in 
subjects impacts their trial drug treatment response. This information may be also be used, for 
example, to develop a better understanding of the safety and efficacy of TAK-954 and other trial 
drugs, to increase understanding of the disease/condition being studied and other related 
conditions, gain a better understanding of the drug pharmacology and for generating information 
needed for research, development, and regulat ory approval of tests to predict response to 
TAK-954. 
Whole blood samples for DNA and RNA isolation will be collected from each consented subject in 
the trial. If necessary and feasible, a second aliquot of blood may be taken at a later time point if 
isolation of DNA from the first sample was not successful or possible.
Since PGx is an evolving science, many genes and their functions are not yet fully understood. 
Future data may suggest a role of these genes in drug response, which may lead to additional 
hypothesis-generating exploratory research and diagnostic development on stored samples.
Detailed instructions for the handling and shippi[INVESTIGATOR_55722].
[IP_ADDRESS] Biological Sample Retention and Destruction
In this trial, specimens for genome/gene analysis w ill be co llected as described in the Laboratory 
Manual. The genetic material will be initially stored at the vendor, or a comparable laboratory, 
under contract to [COMPANY_005], with validated procedures in place, and then preserved and retained at 
the vendor, or a comparable laboratory with validated procedures in place, for up to but not longer 
than [ADDRESS_60809] results collected 
in the trial. The sample and data are linked to personal healt h informat ion with code numbers; the 
samples are stripped of all personal ident ifying information but a key  linking the samples to 
clinical analysis data exists. This lin k means that the subject may be identified but only indirect ly. 
The sample ident ifier will be kept secure by [CONTACT_39805] o f the sponsor.
Subjects who consented and provided a PD sample for DNA and RNA analysis can withdraw their 
consent at any  time and re quest disposal of a stored sample. Any remaining sample that can be 
ident ified as co ming fro m the subject will be destroyed. The trial doctor and sponsor may continue 
to use and distribute any  information and test results gathered before the request to wit hdraw.
9.4 Trial Drug Administration
Eligible subjects will be allocated to trial treatment by [CONTACT_105] -rando m assignment on Day  1 of Trial 
Period 1 and will receive a 0.2 mg single- dose TAK -954 IV on thi s day  and on Day  4 of Trial 
Period 2 at approximately the sam e time (between 0600 and 0900). In Trial Period 2, subjects will 
receive 200 mg QD itraconazole orally on Days 1 to 8 at approximately the same time (between 
0600 and 0900). Itraconazole will be administered as 2 x 100 mg capsules and witnessed by [CONTACT_36284]/or trial staff. The bioavailability of itraconazole when administered as capsules is 
increased under fed co mpared with fasted condit ions and therefore, itraconazole will be 
administered after a standard (moderate -fat) breakfast (consumed wit hin 30 minutes before 
dosing). The TAK -[ADDRESS_60810] (moderate -fat) breakfast 1.5 hours before TAK -954 IV administration in Trial Period 1.
9.5 Confinement
Period 1:
Subjects will report to the clinical research unit (CRU) on Day -1, the day before the scheduled da y 
of administrati on of  the tri al drug at the discret ion of the invest igator. Subjec ts will remain in the 
unit unt il after the PK sample collection at 48 hours after TAK -954 dosing (the morning of Day 3) 
and will return to the clinic for PK sample co llection at 72, 96, and [ADDRESS_60811] igator, subjects may be requested to remain in the CRU lo nger.
TAK -954
Study No. TAK -954-1004 Page 33of 63
Protocol 03 May 2017
CONFIDENTIALPeriod 2:
Subjects will report to the CRU on Day  -1, the day before the scheduled day  of administrati on of  
the trial drug at the discret ion of the invest igator. Subjects will remain in the unit unt il after the PK 
samp le collect ion at 72 hours after TAK -954 dosing (the morning of Day 7). Subjects will return to 
the clinic for PK sample collect ion at 96 and 120 hours and itraconazole administration at 96 hours 
(Day  8). At the di screti on of  the invest igator, subjects may be requested to remain in the CRU 
longer.
TAK -[ADDRESS_60812] who has 
signed inform ed consent to participate in a trial; it does not necessarily have to have a causal 
relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a drug, whet her or 
not it is considered related to the drug.
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a preexist ing condit ion. (Intermittent 
events for pre -exist ing condit ions underlying disease should not be considered AE s.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discont inuat ion or a change in dose of trial medicat ion or a concomitant medicat ion.
Be considered unfavorable by [CONTACT_4168].
Diagnoses versus signs and symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom (s) shoul d be recorded 
appropriately  as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG param eters maybe considered to be AEs if they  are 
judged to be clinically  significant (i e, if som e act ion or intervent ion is required or if the 
investigator judges the change to be bey ond the range of normal physio logic fluctuati on). A 
laboratory  re-test and/or continued monitoring o f an abnormal value are not considered an 
intervent ion. In addit ion, repeated or additional noninvasive te sting for verificat ion, 
evaluat ion, or m onitoring of an abnormalit y is not considered an intervention.
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal fail ure), the di agnosis only  should be 
reported appropriately  as an AE.
Pre-exist ing condit ions:
A pre -exist ing condit ion (present at the time of signing of informed consent) is considered a 
concurrent medical history  condi tion and shoul d NOT be recorded as an AE. A baseline 
evaluat ion (eg, laboratory test, ECG, x -ray) should NOT be recorded as an AE unless related to 
a trial procedure. However, if the subject experiences a worsening or complicat ion of such a 
TAK -954
Study No. TAK -954-1004 Page 35of 63
Protocol 03 May 2017
CONFIDENTIALconcurrent medical history  condi tion, the worsening or com plicat ion should be recorded 
appropriately  as an AE (worsening or complicat ion occurs after informed consent is signed). 
Invest igators should ensure that the event term recorded captures the change in the condit ion 
(eg, “worsening of…”).
If a subject has a pre -exist ing epi[INVESTIGATOR_45283] (eg, asthma, epi[INVESTIGATOR_002]), any occurrence of an 
epi[INVESTIGATOR_55723], serious, or 
severe in nature, that is, invest igators should ensure that the AE term recorded captures the 
change from Baseline in the condit ion (eg “worsening of…”).
If a subject has a degenerat ive concurrent condition (eg, cataracts, rheumatoid arthritis), 
worsening of the condit ion should only be captured as an AE if occurring to a greater exten t to 
that which would be expected. Again, investigators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
Worsening of AEs:
If the subject experiences a worsening or complicatio n of an AE aft er the first administration of 
trial medicat ion or after any  change in trial medication, the worsening or complicat ion shoul d 
be recorded as a new AE. Investigators should ensure that the AE term recorded captures the 
change in the condit ion (eg, “worsening of…”).
Change s in severi ty of AEs:
If the subject experiences a change in the severit y of an AE that is not associated with a change 
in tri al medicat ion, the event should be captured once wit h the m aximum  severi ty recorded.
Prepl anned surgeries or procedures:
Prepl anne d procedures (surgeries or therapi[INVESTIGATOR_014]) that were scheduled before signing of informed 
consent are not considered AEs. However, if a preplanned procedure is performed early (eg, as 
an emergency) because of a worsening of the pre- exist ing condit ion, the worse ning of the 
condi tion shoul d be captured appropriately  as an AE. Com plicat ions result ing from any 
planned surgery  should be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical c ondition 
shoul d not be recorded as AEs but should be documented in the subject’s source documents. 
Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Overdose:
An overdose is defined as a known deliberate or accidental administrati on of  investigational 
drug, to or by  a trial subject, at a dose above that which is assigned to that individual subject 
according to the trial protocol. It is up to the investigator or the reporting physician to decide 
whether a dose is to be considered an overdose, in consultation wit h the sponsor.
All cases of overdose (with or without associated AEs) will be documented on an Overdose 
page of the eCRF, in order to capture this important safet y information consistent ly in the 
TAK -954
Study No. TAK -954-1004 Page 36of 63
Protocol 03 May 2017
CONFIDENTIALdatabase. AEs associated with an overdose will be documented on the AE CRF(s) according to 
Secti on 10.2.
SAEs of overdose should be reported according to the proce dure outlined in Sect ion 10.2.9 .
In the event of drug overdose, the subject should be treated symptomat ically.
10.1.[ADDRESS_60813] medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have c aused death 
if it were m ore severe.
3.Requi res inpat ient HOSPI[INVESTIGATOR_39749].
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.
Is an IMPORTANT MEDICAL EVENT that satisfi es any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospi[INVESTIGATOR_059].
Includes any event or synonym described in the [COMPANY_005] Medically  Significant AE List 
(Table 10.a).
Table 10.a [COMPANY_005] Medically Significant AE List 
Term
Acute respi[INVESTIGATOR_1399]/acute respi[INVESTIGATOR_55724]/ventricular fibrillation/ventricular 
tachycardiaAnaphy lactic shock
Acute renal failure
Malignant hypertension Pulmonary hypertension
Convulsive seizures Pulmonary fibrosis
Agranulocytosis Confirmed or suspected endotoxin shock
Aplastic anemia Confirmed or suspected transmission of infectious agent by 
a medicinal productToxic epi[INVESTIGATOR_194]/Stevens -Johnson syndrome
Neuroleptic malignant syndrome/malignant hyperthermia
Spontaneous abortion/stillbirth and fetal death
TAK -954
Study No. TAK -954-1004 Page 37of 63
Protocol 03 May 2017
CONFIDENTIALAEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and followed up in the same manner.
10.2 AE Procedures
10.2.1 Assigning Severity/Intensity of AEs
The different categories o f severit y/intensity are:
Mild: The event is transient and easily tolerated by [CONTACT_423].
Moderate: The event causes the subject discomfort and i nterrupts the subject’s usual activities.
Severe: The event causes considerable interference with the subject’s usual activities.
10.2.2 Assigning Causality of AEs
The relationship of each AE to trial medicat ion(s) will be assessed using the fo llowing categori es:
Related: An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after withdrawal of the drug), or for which possible involvement of the drug can be 
argued, although factors other than the drug, suc h as underlying diseases, complications, 
concomitant drugs and concurrent treatments, may also be responsible.
Not Related: An AE that does not follow a reasonable temporal sequence from administration of a drug and/o r 
that can reasonably be explained by [CONTACT_1604], such as underlying diseases, complications, 
concomitant drugs and concurrent treatments.
10.2.3 Assigning Relationship to Trial Procedures
Relationship (causalit y) to tri al procedures shoul d be determined for all AEs.
The rel ationship should be as sessed as “Related” if the investigator considers that there is 
reasonable possibilit y that an event i s because of a tri al procedure. Otherwi se, the rel ationship 
shoul d be assessed as “Not Related”.
10.2.[ADDRESS_60814] signs/symptoms were noted by  [CONTACT_3184]/or 
investigator.
10.2.[ADDRESS_60815] died.
10.2.6 Frequency 
Epi[INVESTIGATOR_39751] c AEs (eg, headache) or those that occur repeatedly over a period of consecut ive days are 
intermittent. All other events are continuous.
TAK -954
Study No. TAK -954-1004 Page 38of 63
Protocol 03 May 2017
CONFIDENTIAL10.2.7 Action Concerning Trial Drug 
Drug withdrawn: a trial medicat ion is stopped because of the particular AE.
Dose not changed: the particular AE did not require stoppi[INVESTIGATOR_007] a trial medicat ion.
Unknown: only to be used if it has not been possible to determine what action has been taken.
Not applicable: a trial medicat ion was stopped for a reason other than the particular AE, for 
example, the trial  has been te rminated, the subject died, dosing wit h trial medicati on was 
already stopped before the onset of the AE.
10.2.8 Outcome 
Recovered/reso lved: subject returned to first assessment status with respect to the AE.
Recovering/resolving: the intensit y is lowered by [CONTACT_1734]; the diagnosis has or 
signs/symptom s have alm ost disappeared; the abnormal laboratory  value improved, but has 
not returned to the normal range or to the baseline value; the subject died fro m a cause other 
than the particular AE with the cond ition rem aining “recovering/resolving.”
Not recovered/not resolved: there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, si gns/symptoms, or laboratory  value on the last day  of the observed 
trial period has becom e worse th an when it started; is an irreversible congenital ano maly; the 
subject died fro m another cause with the particular AE state remaining “Not recovered/not 
resolved.”
Reso lved with sequelae: the subject recovered from an acute AE but was left with 
perm anent/s ignificant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).
Fatal : an AE that i s considered as the cause of death.
Unknown: the course of the AE cannot be fo llowed up because o f hospi[INVESTIGATOR_47350]’s participation in the trial.
10.2.9 Collection and Reporting of AEs, SAEs, and Abnormal LFTs
[IP_ADDRESS] Collection Period
Collect ion of AEs (ie, AEs, SAEs, and abnormal LFTs) will commence at the time the subject 
signs the inform ed consent. Routi ne collect ion of AEs will cont inue unt il the Fo llow-up Vi sit 
10-[ADDRESS_60816] discontinues trial participat ion. 
[IP_ADDRESS] Reporting AEs
At each trial visit, the invest igator will assess whether any subject ive AEs have occurred. A neutral 
question, such as “How have y ou been feeling since y our last visit ?” may be asked. Subjects may  
report AEs occurring at any  other time during the tri al. Subjects experiencing an SAE before the 
TAK -[ADDRESS_60817] returned to Baseline or until there is a sat isfactory  explanati on for the 
changes observed. A ll AEs will be documented in the AE page of the eCRF, whether or not the 
investigator concludes that the event is related to the drug treatment. The fo llowing informat ion 
will be documented for each event:
Event term .
Start and stop date and time.
Severit y.
Invest igator’s opi[INVESTIGATOR_3078] n of the causal relationship between the event and administration of trial 
medicat ion(s) (rel ated or not rel ated).
Invest igator’s opi[INVESTIGATOR_3078] n of the causal relationship to trial procedure(s), including the details of 
the suspected proced ure.
Action concerning trial medicat ion.
Outcom e of event.
Seriousness.
[IP_ADDRESS] Reporting SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
procedure outlined below:
A [COMPANY_005] SAE form must be co mpleted, in English and signed by [CONTACT_55740] [ADDRESS_60818] onset or notification of the event. The informat ion should be co mpleted as 
fully as possible but contain, at a minimum:
A short descript ion of the event and the reason why  the event i s cate gorized as serious.
Subject identificat ion number.
Invest igator’s name.
Nam e of the tri al medicat ion(s).
Causalit y assessment.
The SAE form should be transmitted within [ADDRESS_60819] report becomes available at a later date, the 
investiga tor shoul d com plete a follow -up SAE form  or provi de other wri tten docum entati on and 
fax it immediately wit hin 24 hours of receipt. Copi[INVESTIGATOR_1672] 
(eg, ECGs, laboratory  tests, di scharge summary, postmortem results) shoul d be sent to the 
addressee, if requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
[IP_ADDRESS] Reporting of Abnormal LFTs
If a subject is noted to have ALT or AST elevated >3×ULN on [ADDRESS_60820] >3×ULN and total bilirubin >2×ULN for which an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE an d reported 
as per Secti on [IP_ADDRESS] . The i nvest igator must contact [CONTACT_55741] n of the 
relevant subject details and possible al ternative etiol ogies, such as acute viral hepat itis A or B or 
other acute liver disease. Follow -up laboratory  tests as described in Section
 9.2must also be 
perfor med. In addit ion, an LFT Increases eCRF must be completed and transmitted with the 
[COMPANY_005] SAE form (as per Section 10.2.10 )
. 
10.2.[ADDRESS_60821] ions 
(S[LOCATION_003]Rs) and any other applicable SAEs to regulatory  authori ties, invest igators and IRBs or 
Independent Ethics Committee s (IECs), as applicable, in accordance wit h nat ional regulations in 
the countries where the trial is conducted. Relat ive to the first awareness of the event by/or further 
provi sion to the sponsor or sponsor’s designee, S[LOCATION_003]Rs will be submitted within [ADDRESS_60822] a copy  of all expedited reports to his or her IRB or IEC in accordance wit h nat ional 
regul ations.
TAK -954
Study No. TAK -954-1004 Page 41of 63
Protocol 03 May 2017
CONFIDENTIAL11.0 STATISTICAL METHODS
11.1 Statistical and Analytical Plans
A stati stical analysis plan (SAP) will be prepared and finalized before database lock. This 
docum ent will provi de further details regarding the definit ion of analysis variables and analysis 
methodol ogy to address all trial object ives.
A targeted data review will be conducted before database lock. This review will assess the 
accuracy  and com pleteness of the trial databa se, subject evaluabilit y, or appropri ateness of the 
planned statistical methods.
11.1.[ADDRESS_60823] sh ould be included in the 
PK analyses; however, data for all subjects will be presented in the data list ings.
11.1.[ADDRESS_60824] atistics 
(number of subjects, mean, SD, median, minimum, and maximum) will be presented for 
continuous variables (eg, age, weight, and BMI), and the number and percentage of subjects within 
each category  will be presented for categorical variables (eg, sex , ethnicit y, and race). Individual 
subject demographic and baseline characterist ic data will be provided in the data list ings.
11.1.[ADDRESS_60825] of itraconazole on TAK -954 PK, paired t -tests and associated CIs 
will be determined on the natural logarithms of C maxand area under the concentration -time curses 
to assess the exposure between regimens (TAK- 954 al one and TAK -954 wi th itraconazol e). The 
geom etric mean of  the rel ative bioavailabilit y of the TAK -954 wi th itraconazol e regimen relative 
to the TAK -954 al one regimen and the associated 90% CIs will be determined by [CONTACT_55742] -transformed parameters.
A more detailed analysis will be presented in the SAP. Ad ditional analyses will  be included, if 
appropriate.
11.1.4 Safety Analysis
The safet y set will be used for all summaries of safety  parameters. These summaries will be 
presented by [CONTACT_4129] -954 al one, i traconazo le alone, and TAK -954 wi th itraconazol e.
[IP_ADDRESS] AEs
All AEs will be coded by  [CONTACT_55743] (SOC) and preferred term (PT) using the Medical 
Dictionary for Regulatory  Activities(MedDRA). Treatment- emergent adverse events (TEAEs) 
with onset occurring within 30 days (onset date minus last date of dose +1 ≤30) after the last dose 
of trial drug will be included in the summary tables. All AEs will be in the list ings. TEAEs will be 
summarized by  [CONTACT_3592]. The following summary  tables will be included in the report: 
summary of TEAEs and drug -related AEs, relat ionship o f AEs to trial drug (related vs not related), 
severit y of AEs, and related SAEs. Data list ings will be provided for all AEs including TEAEs, 
AEs leading to trial drug discont inuat ion, and SAEs. 
[IP_ADDRESS] Clinical Laboratory Evaluation
Baseline, postdose, and change fro m Baseline to postdose laboratory  data will be summarized by  
[INVESTIGATOR_24858]. All clinical laboratory  data will be provi ded in the data list ings.
[IP_ADDRESS] Vital Signs
Baseline, postdose, and changes from Baseline in vital sign measurements will be summarized. All 
vital sign data will be provided in the data list ings.
[IP_ADDRESS] ECGs
Baseline, postdose, and changes from Baseline in quant itative ECG parameters will be 
summarized by [INVESTIGATOR_24858]. Shift tables for each will be generated to show the invest igator’s ECG 
interpretati ons at each po stdose collection by [CONTACT_55744].
All ECG data will be provided in the data list ings.
TAK -954
Study No. TAK -954-1004 Page 43of 63
Protocol 03 May 2017
CONFIDENTIAL11.2 Interim Analysis and Criteria for Early Termination
No formal interim analyses will be conducted. 
11.3 Determination of Sample Size
Approximately  10 subjects will com plete thi s trial . With this sample size, a 2 -sided 95.0% CI for 
the geom etric mean rati o of Cmaxfor TAK -[ADDRESS_60826] 90% probabilit y of excluding 1.25 (the upper bound of the bioequivalence range) if 
itraconazo le increases the C maxfor TAK -[ADDRESS_60827] 50%. This calculat ion assumes that the CI 
is based on the t statist ic, that the distance fro m the mean to the lower bound of the CI on the 
natural -log scale is 0.182, and that the true SD o f differences on the natural -log scale is 0.[ADDRESS_60828] variat ion observed for area under the concentration -time curve fro m time 0 to time t in 
that coho rt (SD=0.129), a 2 -sided 95.0% CI for the geometric mean ratio of AUC ∞for TAK -[ADDRESS_60829] greater than 99% probabilit y of 
excluding 1.25 if itraconazo le increases AUC ∞for TAK -[ADDRESS_60830] 50%. 
Subject s who drop out may be replaced at the discretion of the sponsor in consultat ion with the 
investigator. Subjects who replace dropouts will begin the trial as a new subject in Trial Period 1. 
TAK -[ADDRESS_60831] to review by  [CONTACT_55745]’s designee, including but not limited to the Invest igator’s Binder, trial drug, subject 
medical records, informed consent documentation, and review of eCRFs and associated source 
docum ents. It i s important that the invest igator and other trial personn el are available during the 
monitoring visits and that sufficient time is devoted to the process.
12.[ADDRESS_60832] to trial subjects. Should o ther unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
Significant deviat ions include, but are not limited to, those that invo lve fraud or misconduct, 
increase the healt h risk to the subject, or confound interpretation of primary tri al assessment. 
12.[ADDRESS_60833] the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the trial. In 
addition, there is the possibilit y that this trial may  be inspected by  [CONTACT_55746], including 
those of foreign governments (eg, the FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
trial site is contact[CONTACT_4190] a regulatory  body , the sponsor should be notified 
immediately . The investi gator guarantees access for qualit y assurance auditors to all trial 
docum ents as described in Sect ion 12.1.
TAK -[ADDRESS_60834] for the individual part icipants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the International Conference on Harmo nisat ion (ICH) Harmonised Tripartite 
Guideline for GCP. Each investigator will conduct the trial according to applicable local or 
regional regulatory  requi rements and align his or her co nduct in accordance wit h the 
“Responsibilit ies of the Investigator” that are listed in Appendix A. The principles of Helsinki are 
addressed through the protocol and th rough appendi ces containing requirements for informed 
consent and invest igator responsibilit ies.
13.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing regio n. The sp onsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has direct participation in this trial, written notificatio n regarding his or her abst inence fro m vo ting 
must al so be obtained. Those Americas sites unwilling to provide names and tit les of all members 
because of privacy  and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or comparable number assigned by [CONTACT_55747].
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Invest igator’s Brochure, a copy o f 
the informed consent form, and, if applicable, subject recruit ment materials and/or advertisements 
and other documents required by [CONTACT_1763], must be submitted to a 
central  or local IRB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and
subject informed consent must be obtained and submitted to the sponsor or designee before 
commencement of the trial (ie, before shipment of the sponsor -supplied drug or trial -specific 
screening activit y). The IRB or IEC approval must refer to the trial by [CONTACT_55748] t itle, number, 
and versio n date; ident ify versio ns of other documents (eg, informed consent form) reviewed; and 
state the approval date. The sponsor will ship drug/notify site once the sponsor has confirmed the 
adequacy  of site regul atory  docum entati on and, when applicable, the sponsor has received 
permission fro m competent authori ty to begin the trial. Unt il the site receives drug/notificat ion no 
protocol  activit ies, including screening, may  occur.
Sites m ust adhere to all requirements stip ulated by  [CONTACT_4195]. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the informed consent 
form, recrui tment m aterials intended for viewing by  [CONTACT_1766], l ocal safety  reporti ng requirements, 
reports and updates regarding the ongoing review of the trial at intervals specified by [CONTACT_39820], and submissio n of the investigator’s final status report to IRB or IEC. All 
IRB and IEC approvals and relevant documentation for these items must be provided to the 
sponsor or its designee.
Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by [CONTACT_4197].
TAK -[ADDRESS_60835] authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the trial. The informed consent form and the subject informat ion sheet (if applicable) 
further explain the nature of the trial, its object ives, and potential risks and benefit s, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the 
inform ed consen t form and, if applicable, the subject authorization form. The informed consent 
form, subject authorizat ion form (if applicable), and subject information sheet (if applicable) must 
be approved by [CONTACT_55749].
The informed consent form , subject authori zation form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsibilit y of the invest igator to explain the detailed ele ments of the informed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate b y the IRB or IEC. In the event the subject is not capable of rendering 
adequate written informed consent, then the subject’s legally  acceptable representative may 
provi de such consent for the subject in accordance with applicable laws and regulat ions.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details of the trial, and (2) decide whether or not to participate in the trial. If the 
subject, or the subject’s legally  acceptable represen tative, determines he or she will part icipate in 
the trial, then the informed consent form and subject authorization form (if applicable) must be 
signed and dated by  [CONTACT_423], or the subject’s legally  acceptable representative, at the time of 
consent an d before the subject entering into the trial. The subject or the subject’s legally acceptable 
representative should be instructed to sign using their legal names, not nicknames, using blue or 
black ballpo int ink. The investigator must also sign and date th e informed consent form and 
subject authorizat ion (if applicable) at the time of consent and before subject entering into the trial; 
however, the sponsor may  allow a designee of the investi gator to si gn to the extent permitted by  
[CONTACT_1289].
Once signe d, the ori ginal  informed consent form , subject authori zation form (if applicable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copi[INVESTIGATOR_1681], the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
TAK -[ADDRESS_60836]’s legally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent was ob tained shoul d be recorded in the subject’s medical 
record, and the subj ect shoul d receive a copy  of the revised informed consent form.
Subjects who consented and provided a PGx sample for DNA and RNA analysis can withdraw 
their consent and request disposal o f a stored sample at any  time before analysis. Notify  the 
sponsor of consent withdrawal.
13.[ADDRESS_60837]’s right to protection 
against invasio n of privacy. Throughout this trial, a subject’s source data will only be linked to the 
sponsor’s clin ical trial database or documentation via a unique ident ificat ion number. As permitted 
by [CONTACT_39823], limited subject attributes, such as sex, age, or date of birth, 
and subject init ials may be used to verify the subject and accurac y of the subject’s unique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  autho rity (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n 
and discharge summaries for hospi[INVESTIGATOR_45291] a subject’s trial part icipation, 
and autopsy  reports. Access to a subject’s original medical records r equires the specific 
authori zation of the subject as part of the informed consent process (see Section 13.2).
Copi [INVESTIGATOR_39757] (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s eCRF).
13.[ADDRESS_60838] igator from the trial. During and after the trial, only the sponsor may make trial 
inform ation available to other trial investigators or to regulatory  agencies, except as required by  
[CONTACT_4201]. Except as otherwise allowable in the clinical trial site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or trial result s, other 
than tri al recrui tment materi als and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any  data and informat ion fro m the trial (including data and informat ion 
generated by  [CONTACT_3170]) without the consent of th e invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
TAK -954
Study No. TAK -954-1004 Page 48of 63
Protocol 03 May 2017
CONFIDENTIALthis secti on and the Clini cal Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
13.4.2 Clinical Trial Registration 
In order to ensure that informat ion on clinical trials reache s the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, [COMPANY_005] will, at a minimum, register all 
intervent ional clinical trials it sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly  accessible we bsites before start of the trial, as defined in [COMPANY_005] Policy/Standard. [COMPANY_005] 
contact [CONTACT_4203], along with invest igator’s cit y, state (for American investigators), country, and 
recrui ting status will be registered and available for public viewing. 
Forsome registries, [COMPANY_005] will assist callers in lo cating trial sites closest to their ho mes by 
[CONTACT_39824], address, and phone number to the callers request ing trial 
inform ation. Once subjects receive invest igator contact [CONTACT_4203], they may call the site 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of trial enr ollment, they should be referred to the sponsor.
Any invest igator who objects to the sponsor providing this informat ion to callers must provide the 
sponsor with a written notice request ing that their informat ion not be listed on the registry  site.
13.4.[ADDRESS_60839] the results of clinical trials on ClinicalTrials.gov or other publicly accessible 
websites, as required by [CONTACT_39825]/Standard, applicable laws and/or regulat ions.
13.[ADDRESS_60840] is participat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical trial insurance against the ris k of injury to tri al subjects. Refer to the 
trial site agreement regarding the sponsor’s policy on subject compensat ion and treatment for 
injury . If the invest igator has questions regarding this policy, he or she should contact [CONTACT_39826]’s des ignee.
TAK -[ADDRESS_60841] Type/Role Contact
[CONTACT_55750], Inc.
Fax: 224-[ADDRESS_60842] igator’s Brochure, package 
insert and any  other product information provided by  [CONTACT_456]. I agree to conduct this trial in 
accordance with the requirements of this prot ocol and also to protect the rights, safet y, privacy, 
and well -being o f trial subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinic al Practi ce: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting SAEs defined in Section 10.2.10 of this protocol .
Terms outlined in the trial site agreement.
Responsibilit ies o f the Invest igator ( Appendix A).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in
 Appendix Cof this protocol .
Signature [CONTACT_4235] (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
TAK -[ADDRESS_60843] of A bbreviations
5-HT4 serotonin type 4
β-hCG β–human chorionic gonadotropin
AE adverse event
Aet amount of drug excreted in urine from time [ADDRESS_60844] measurable time point.
AUC t area under the concentration -time curve from time 0 to time t.
AUC ∞ area under the concentration -time curve from time [ADDRESS_60845]
MedDRA Medical Dictionary for Regulatory Activities
MTD maximum tolerated dose
PGx pharmacogenomics
PK pharmacokinetic(s)
PT preferred term
QD once daily
QTcF QT interval with Fridericia correction method
RBC red blood cell
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analysis plan
SBP systolic blood pressure
SOC system organ class
S[LOCATION_003]R suspected unexpected serious adverse reactions
t1/[ADDRESS_60846] ly onto e CRFs.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by [CONTACT_1748] (or designees) and will be answered by [CONTACT_779]. 
Correcti ons are recorded i n an audit trail that captures the old informat ion, the new informat ion, 
ident ificat ion of the person making the correction, the date the correction was made, and the reason 
for change. Reasons for si gnificant correcti ons shoul d additionally be included. 
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the investigator must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs .
After the lock of  the clinical trialdatabase, any  change of, m odificat ion of, or addit ion to the data 
on the eCRFs should be made by [CONTACT_55751]. The principal invest igator must review the data change for completeness and accuracy, 
and must sign and date . 
eCRFs will be reviewed for completeness and acceptabilit y at the trial site during periodic visits by 
[CONTACT_55752]. The sponsor or i ts desi gnee will be permi tted to revi ew the subject’s medical and 
hospi [INVESTIGATOR_55725]. The com pleted eCRFs are 
the sole property  of the sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the sponsor.
16.[ADDRESS_60847] igator agrees to keep the records stipulated in Section 16.1 and those documents that 
include (but are not limited to) the trial- specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and date d informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms), 
electroni c copy  of eCRFs, incl uding the audi t trail, and detailed records of drug disposit ion to 
enable ev aluat ions or audits from regulatory  authori ties, the sponsor or its designees. Any  source 
TAK -[ADDRESS_60848]’s chart to ensure long -term legibilit y. Furthermore, ICH 
E6 Secti on 4.9.5 requi res the investigator to retain essent ial docum ents specified in ICH E6 
(Secti on 8) until at least [ADDRESS_60849] igator and sponsor.
Refer to the Clinical Study Site Agreement for the sponsor’s requirements on record retention. The 
investigator a nd the head of the institution should contact [CONTACT_4182] m the 
sponsor before disposing of any  such documents.
TAK -954
Study No. TAK -954-1004 Page 55of 63
Protocol 03 May 2017
CONFIDENTIAL17.0 REFERENCES
1.Barton RG. Nutrition support in crit ical illness. American Society  for Parenteral  and Entera l 
Nutri tion 1994;168:659 -64.
2.Harrington L. Nutrit ion in cr itically ill adults: key processes and outcomes. Crit Care Nurs Clin 
North Am 2004;16(4):459-65.
3.Slone DS. Nutri tional support of the cri tically  ill and injured pat ient. Crit Care Clin 
2004;20 (1):135 -57.
4.Beatti e DT, Armstrong SR, Vickery  RG, Tsuruda PR, Campbell CB, Richardson C, et al. The 
Pharmaco logy of TD-8954, a Potent and Selective 5 -HT(4) Receptor Agonist with 
Gastrointestinal Prokinetic Properties. Front Pharmaco l 2011;2:25.
TAK -[ADDRESS_60850] igator s by [CONTACT_45348] “Statement of Invest igator” (Form FDA 1572), which must be completed and 
signed before the invest igator may participate in this trial.
The invest igator agrees to assume the fo llowing responsibilit ies by [CONTACT_2960] a Form FDA 1572:
1.Conduct the trial in accordance with the protocol.
2.Personally conduct or supervise the staff that will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
trial-related duti es and funct ions, the invest igator/inst itution shoul d ensure that this individual 
or party  is qualified to perform those trial -related duti es and funct ions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions performed and a ny 
data generated.
4.Ensure that trial -related procedures, including trial specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, before the receipt of written 
approval  from relevant governing bodies/authorit ies.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct of the trial are informed of 
these obligat ions.
6. Secure prior approval of the trial and any changes by [CONTACT_4215]/IEC that conform to 
21 Code of Federal Regulations (CFR) Part 56, ICH, and l ocal regul atory  requi rements.
7.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least yearly reports on the progress of the trial to the 
IRB/IEC, and issue a final report within [ADDRESS_60851]’s medical chart. Valid informed consent is the most current 
versio n approved by [CONTACT_1201]/IEC. Each informed consent form should contain a subject 
authori zation sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
trial. If an inform ed consent form  does not include such a subje ct authori zation, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the trial, including 
eCRFs, hospi[INVESTIGATOR_1097], laboratory  resul ts, etc, and maintain these data for a minimum o f 
TAK -[ADDRESS_60852]:
1.A statement that the trial invo lves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the trial.
7.A descript ion of th e subject’s responsibilit ies.
8.A descript ion of the conduct of the trial.
9.A descript ion of the possible side effects of the treatment that the subject may receive.
10.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embryo, fetus, or nursing infant.
11.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of thi s.
12.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
13.A statement describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regul atory  agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By  [CONTACT_2960] a written informed consent form, the 
subject or the subject’s legally acceptable representa tive is authorizing such access.
14.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are available if injury  occurs and, if 
so, what they  consist of or where f urther informat ion may be obtained.
15.The ant icipated prorated payment(s), if any, to the subject for participat ing in the trial.
16.The ant icipated expenses, if any , to the subject for parti cipat ing in the trial.
17.An explanat ion of whom to contact [CONTACT_39831] 
(invest igator), subject’s rights, and IRB/IEC and who m to contact i n the event of a 
research -related inj ury to the subject.
18.A statement that participation is vo luntary, that refusal to participate will invo lve no penalt y or 
loss of benefits to which the subject otherwise is entit led, and that the subject may discont inue 
participat ion at any  time wi thout penal ty or loss of benefits to which the subject is otherwise 
entitled.
TAK -[ADDRESS_60853]’s decisio n towithdraw fro m the research and procedures for 
orderly terminat ion of part icipation by [CONTACT_423].
20.A statement that the subject or the subject’s legally acceptable representative will be informed 
in a timely  manner if informat ion beco mes available that may be relevant to the subject’s 
willingness to continue participat ion in the trial.
21.A statement that results of PGx analysis will not be disclosed to an individual, unless 
prevailing laws require the sponsor to do so.
22.The foreseeable circumstances or reas ons under which the subject’s participat ion in the trial 
may be terminated.
23.A wr itten subject authorization (eit her contained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible us es and 
disclosures of the subject’s personal information (including personal health informat ion) for 
purposes of conduct ing the trial. The subject authorizat ion must contain the fo llowing 
statements regarding the uses and disclosures of the subject’s perso nal informat ion:
a)that personal information (including personal healt h informat ion) may be processed by  [CONTACT_45351] y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) [COMPANY_005], its affiliates, and 
licensing partners; (2) business partners assist ing [COMPANY_005], its affiliates, and licensing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level o f protecti on as the data protection laws wit hin this country; 
however, [COMPANY_005] will make every  effort to ke ep your personal  information confident ial, 
and y our name [CONTACT_39846] [CONTACT_2371];
c)that personal information (including personal healt h informat ion) may be added to 
[COMPANY_005]’s research databases for purposes of developi [INVESTIGATOR_007] a better understanding of the 
safet y and effect iveness o f the trial medicat ion(s), studying other therapi[INVESTIGATOR_39759], 
developi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that subjects agree not to r estrict the use and disclo sure of their personal informat ion 
(including personal healt h informat ion) upon withdrawal fro m the trial to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
e)that the subject’s ident ity will remain confident ial in the event that trial results are 
published.
24.Male subjects must use adequate contraception (as defined in the informed consent) from 
Screening, throughout the duration of the trial, and for [ADDRESS_60854] igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
[LOCATION_008], [LOCATION_002], and Japan), including the following:
[COMPANY_005], its affiliates, and licensing partners.
Business partners assist ing [COMPANY_005], its affiliates, and licens ing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  [CONTACT_39833]:
Assessment of th e suitabilit y of invest igator for the trial and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the trial.
Analysis, review, and verificat ion of the trial results.
Safety reporti ng and pharmacovigilance relat ing to the trial.
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the trial.
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other m edicati ons used in other clinical studies that may contain 
the sam e chemical com pound present in the trial medicat ion.
Inspect ions and invest igations by [CONTACT_55753].
Self-inspect ion and internal audit within [COMPANY_005], its affiliates, and licensing partners.
Archiving and audit of trial records.
Posting investigator site contact [CONTACT_4203], trial details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal informatio n by [CONTACT_47407].
TAK -954
Study No. TAK -954-1004 Page 62of 63
Protocol 03 May 2017
CONFIDENTIALAppendix DPregnancy and Contraception
Contraception and Pregnancy Avoidance Procedure
Female Subjects and Their Male Partners
Female subjects of childbearing po tential are excluded from  this tri al; there are no requirements 
for contracepti on or pregnancy  avoi dance.
Male Subjects and Their Female Partners
From  signing of informed consent, throughout the duration of the trial, and for [ADDRESS_60855] dose of trial drug, nonsterilized** male subjects who are sexually active with 
a female partner of childbearing potential must use barrier contraception (eg, condom with or 
without spermicidal cream or jelly ). In addi tion, they  must be advised n ot to donate sperm  during 
this period. Women of childbearing potential who are partners of male subjects are also advised to 
use addit ional contraception as shown in the list containing highly effect ive/effect ive 
contraception below.
** Sterilized males sh ould be at least [ADDRESS_60856] –bilateral vasectomy and have confirmed that they 
have obtained documentation of the absence of sperm in the ejaculate or have had bilateral 
orchi dectomy .
1.Highly effect ive methods of contraception are defined as “those, alone or in combinat ion, that 
resul t in a l ow failure rate (i e, less than 1% failure rate per y ear when used consistent ly and 
correctly ). In this tri al, where m edicati ons and devices containing hormones are included, 
females o f childbearing potential who are partn ers of male subjects are advised to use 
additional contracepti on chosen from the list belo w: 
Nonhorm onal methods: 
–Intrauterine device.
–Bilateral tubal occlusio n. 
Horm onal methods: 
–Combined (estrogen and progestogen) hormonal contraception associated wi th 
inhibit ion of ovulation initiated at least [ADDRESS_60857] dose of trial drug.
Oral. 
Intravaginal (eg, ring).
Transdermal. 
–Progestogen -only hormonal contracepti on associ ated wi th inhibit ion of ovulation 
initiated at least [ADDRESS_60858] dose of trial drug.
Oral. 
Injectable.
TAK -954
Study No. TAK -954-1004 Page 63of 63
Protocol 03 May 2017
CONFIDENTIALImplantable.
2.Since genotoxicit y/teratogeni city/embry otoxi city is unlikely  to be caused by  [CONTACT_55754], additional effect ive methods of contraception (there may be a higher than 
1% failure rate) that may be chosen by [CONTACT_55755] a male subject are: 
Doubl e-barrier method (contraceptive sponge, diaphragm or cervical cap wit h spermicidal 
jellies or creams).
Progestogen only hormonal contraception, where inhibit ion of ovulat ion is not the p rimary 
mode of act ion. 
3.Unacceptable methods of contraception are:
Periodic abst inence (eg, calendar, ovulat ion, symptothermal, postovulat ion methods).
Spermicides only .
Withdrawal.
No m ethod at all.
Use of female and male condoms together.
Cap/di aphragm/s ponge wi thout spermicide and wit hout condom .
4.Male subjects will be provided wit h information on highly effective/effect ive methods of 
contraception as part of the subject informed consent process and will be asked to sign a 
consent form stating that they  understand the requirements for avo idance of pregnancy and 
sperm  donat ion during the course of the trial.
5.Male subjects will receive continued guidance with respect to the avoidance of pregnancy and 
sperm  donat ion as part of the trial procedures. Such guida nce should include a reminder of the 
following:
Contraceptive requirements of the trial.
Reasons for use of barrier methods (ie, condom) in males with pregnant partners.
Assessment of subject compliance through questions such as:
–Have you used the contrace ption consistent ly and correctly since the last visit ?
–Have you forgotten to use contraception since the last visit ?
 䢢
䢢䢢䢢
䢢
䢢䢢
䢢
(/(&7521,& 6,*1$785(6 
Signed by [CONTACT_4232] 
(dd-MMM-yyyy HH:mm ‘UTC’) 

  

  

  

   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   



GGEG䣃䢢䣕䣫䣰䣩䣮䣧䢯䣕䣧䣳䣷䣧䣰䣥䣧䢮䢢䣑䣲䣧䣰䢯䣎䣣䣤䣧䣮䢮䢢䢴䢯䣒䣧䣴䣫䣱䣦䢢䣅䣴䣱䣵䣵䣱䣸䣧䣴䢢䣖䣴䣫䣣䣮䢢䣶䣱䢢䣇䣸䣣䣮 䣷䣣䣶䣧䢢䣶䣪䣧䢢䣇䣨䣨䣧䣥䣶䢢䣱䣨䢢䣶䣪䣧䢢䣒䣱䣶䣧䣰䣶䢢䣅䣻䣶䣱䣥䣪䣴䣱䣯䣧
䣒䢯䢶䢷䢲䢢䢵䣃䢶䢢䣋䣰䣪䣫䣤䣫䣶䣱䣴䢢䣋䣶䣴䣣䣥䣱䣰䣣䣼䣱䣮䣧䢢䣱䣰䢢䣶䣪䣧䢢䣒䣪䣣䣴䣯䣣䣥䣱䣭䣫䣰䣧䣶䣫䣥䣵䢢䣱䣨䢢䣖䣃䣍 䢢䢻䢷䢶䢢䣫䣰䢢䣊䣧䣣䣮䣶䣪䣻䢢䣃䣦䣷䣮䣶䢢䣕䣷䣤䣬䣧䣥䣶䣵
6WDWLVWLFDO$SSURYDO 0D\87&
&OLQLFDO3KDUPDFRORJ\$SSURYDO 0D\87&
&OLQLFDO93$SSURYDO 0D\87&[COMPANY_003]